Friday, October 18, 2019 Daily Archives

Combigene teams with Cobra and NBR on epilepsy gene therapy

by

Cobra Biologics will produce the AAV viral vector for Combigene’s epilepsy gene therapy from its facilities in Keele, UK. Nordic gene therapy company Combigene’s CG01 candidate is based on an adeno-associated viral vector (AAV) which administers a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the part of the brain where epileptic seizures begin. The project has received funding from the European Union’s Horizon 2020 research and innovation program and the manufacturing process was developed at the…

October 18, 2019

CAR-T at a crossroad as industry looks to allogeneic

by

As cell therapies move through the clinic towards commercialization, respondents to a KNect365 industry survey are beginning to look to allogeneic – or off-the-shelf – products as the next big thing. Almost 200 people contributed to the Cell Therapy Analytics Report from KNect365, revealing their current position within the burgeoning cell and gene therapy space and offering up their thoughts and predictions for the future. The majority worked within companies developing oncology products, and the largest group – 41% –…

October 18, 2019